27 MayANI acquires approved ANDA for Flecainide Acetate tablets USP ANI Pharmaceuticals.

today announced that it has obtained the approved abbreviated brand-new drug software for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. According to IMS Wellness, the overall market because of this product was around $39 million in 2014. Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, mentioned, ‘This acquisition additional expands our near-term generic pipeline. We intend to re-launch the product within the next 12 months. We are excited that this transaction further extends the ANI-Teva relationship.’ ANI has forty-seven generic medication products under development addressing a total annual market size of around $3.0 billion, based on data from IMS Health..Home Oversight Committee is arriving heat on Minnesota and many other claims with troubled medical health insurance exchanges. U.S. Rep. Darrell Issa of California is usually sending letters to 10 governors, including Gov. Mark Dayton, and the District of Columbia's mayor, his workplace said. The letters seek internal files and communications between state employees and contractors and Obama administration officials relating to their insurance exchanges from Might 1, 2013 to provide . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is an application of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.1 million registered nurses.